Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw

نویسندگان

  • Seung Jae Paek
  • Won-Jong Park
  • Ho-Sung Shin
  • Moon-Gi Choi
  • Kyung-Hwan Kwon
  • Eun Joo Choi
چکیده

OBJECTIVES The objective of this study was to retrospectively investigate the association of diseases having an influence on inhibition of angiogenesis such as hypertension, diabetes mellitus type II, hypercholesterolemia, and rheumatoid arthritis (RA) with the development of osteonecrosis of the jaws. MATERIALS AND METHODS The 135 patients were allocated into 4 groups of bisphosphonate-related osteonecrosis of the jaw (BRONJ) group (1A); non-BRONJ group (1B); osteonecrosis of the jaw (ONJ) group (2A); and control group (2B), according to histologic results and use of bisphosphonate. This retrospective study was conducted with patients who were treated in one institute from 2012 to 2013. Fisher's exact test and logistic regression analysis were used to analyze the odds ratios of diseases having an influence on inhibition of angiogenesis for development of ONJ. RESULTS The effects of diabetes and hypertension were not statistically significant on development of ONJ. When not considering bisphosphonate use, RA exhibited a high odds ratio of 3.23 (P=0.094), while hyperlipidemia showed an odds ratio of 2.10 (P=0.144) for development of ONJ. More than one disease that had an influence on inhibition of angiogenesis showed a statistically significant odds ratio of 2.54 (P=0.012) for development of ONJ. CONCLUSION Patients without diseases having an influence on inhibition of angiogenesis were at less risk for developing ONJ.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bevacizumab, sunitinib: osteonecrosis of the jaw.

Bevacizumab and sunitinib inhibit angiogenesis by blocking the action of vascular endothelial growth factor (VEGF) (1,2). Bevacizumab is an antiVEGF monoclonal antibody. Sunitinib inhibits the tyrosine kinases linked to the VEGF receptor. Both of these cancer drugs have been linked to osteonecrosis of the jaw (3,4). The British drug regulatory agency (MHRA) has reported 55 cases of osteonecrosi...

متن کامل

Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Introduction Despite significant treatment advances and survival improvement in a variety of pediatric CNS tumors, there remains a large number of children who succumb to their disease. A variety of novel biologic and targeted therapies have been evaluated in an effort to improve survival. One class of therapeutics that is being widely explored is antiangiogenic agents. Angiogenesis is the deve...

متن کامل

Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview

Medication-related osteonecrosis of the jaws (MR-ONJ) is one of the most relevant side effects of bisphosphonate therapy; it is clinically defined as a non-healing wound in combination with an avascular and necrotic jaw within ongoing bisphosphonate therapy or after completed bisphosphonate therapy. Different theories concerning the development of MR-ONJ have been reported, while the exact path...

متن کامل

Silent osteonecrosis of the femoral head following high-dose corticosteroid (CS) medications

  Background: Osteonecrosis (ON) is known to be one of the most disabling complications following corticosteroid (CS) medications. However, evidence regarding risk of asymptomatic prevalence of ON among different diseases and the impact of variable steroid regimens are conflicting. We aimed to determine the prevalence of ON of femoral head in asymptomatic patients with systemic rheumatic diseas...

متن کامل

Medication-Related Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a common side effect of antiresorptive drugs that are administered to cancer patients for bone metastasis, multiple myeloma, and osteoporosis. Since both bisphosphonate (BP) and denosumab show anti-bone resorption effects with ONJ, antiresorptive agent-related ONJ (ARONJ) has been suggested as a comprehensive term encompassing both BP-related osteonecrosis of t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 42  شماره 

صفحات  -

تاریخ انتشار 2016